MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 85 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,273 | -96.9% | 655 | -95.8% | 0.00% | – |
| Q2 2023 | $170,459 | -76.5% | 15,696 | -85.1% | 0.00% | -100.0% |
| Q1 2023 | $726,473 | +140.8% | 105,286 | +38.9% | 0.00% | – |
| Q4 2022 | $301,696 | +429.3% | 75,803 | +791.4% | 0.00% | – |
| Q3 2022 | $57,000 | +714.3% | 8,504 | +490.6% | 0.00% | – |
| Q2 2022 | $7,000 | -75.0% | 1,440 | -51.7% | 0.00% | – |
| Q1 2022 | $28,000 | -79.1% | 2,980 | -73.5% | 0.00% | – |
| Q4 2021 | $134,000 | -30.2% | 11,240 | -33.3% | 0.00% | – |
| Q3 2021 | $192,000 | +90.1% | 16,863 | +199.6% | 0.00% | – |
| Q2 2021 | $101,000 | +55.4% | 5,629 | +32.8% | 0.00% | – |
| Q1 2021 | $65,000 | -44.0% | 4,239 | -55.5% | 0.00% | – |
| Q4 2020 | $116,000 | +673.3% | 9,521 | +692.8% | 0.00% | – |
| Q3 2020 | $15,000 | – | 1,201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |